These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
709 related articles for article (PubMed ID: 21245739)
1. Celecoxib impairs heart development via inhibiting cyclooxygenase-2 activity in zebrafish embryos. Xu DJ; Bu JW; Gu SY; Xia YM; Du JL; Wang YW Anesthesiology; 2011 Feb; 114(2):391-400. PubMed ID: 21245739 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Huang WF; Hsiao FY; Wen YW; Tsai YW Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817 [TBL] [Abstract][Full Text] [Related]
5. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Kivitz AJ; Espinoza LR; Sherrer YR; Liu-Dumaw M; West CR Semin Arthritis Rheum; 2007 Dec; 37(3):164-73. PubMed ID: 17570469 [TBL] [Abstract][Full Text] [Related]
6. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799 [TBL] [Abstract][Full Text] [Related]
9. Cutaneous and intra-abdominal abscess formation in rats following radio frequency [corrected] ablation of liver tumors in combination with celecoxib treatment. De Heer P; Sandel MH; Speetjens FM; Koudijs MM; Putter H; Ensink GN; Van de Velde CJ; Kuppen PJ In Vivo; 2006; 20(3):373-5. PubMed ID: 16724673 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832 [TBL] [Abstract][Full Text] [Related]
11. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Zhang L; Bertucci AM; Smith KA; Xu L; Datta SK Arthritis Rheum; 2007 Dec; 56(12):4132-41. PubMed ID: 18050205 [TBL] [Abstract][Full Text] [Related]
12. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964 [TBL] [Abstract][Full Text] [Related]
13. Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats. Nishiyama T Acta Anaesthesiol Scand; 2006 Feb; 50(2):228-33. PubMed ID: 16430547 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial. Chung JW; Yang HM; Park KW; Lee HY; Park JS; Kang HJ; Cho YS; Youn TJ; Koo BK; Chae IH; Choi DJ; Oh BH; Park YB; Kim HS Circ Cardiovasc Interv; 2010 Jun; 3(3):243-8. PubMed ID: 20484099 [TBL] [Abstract][Full Text] [Related]
18. Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats. Bykov IL; Palmen M; Rainsford KD; Lindros KO Inflammopharmacology; 2006 Mar; 14(1-2):36-41. PubMed ID: 16835711 [TBL] [Abstract][Full Text] [Related]
19. Risks and benefits of celecoxib to prevent colorectal adenomas. Andersohn F; Suissa S; Garbe E N Engl J Med; 2006 Nov; 355(22):2371; author reply 2371-3. PubMed ID: 17135594 [No Abstract] [Full Text] [Related]
20. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Rattray B; Nugent DJ; Young G Haemophilia; 2006 Sep; 12(5):514-7. PubMed ID: 16919082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]